ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1662

Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission

Laura M.M. Steunebrink1, Peter M. ten Klooster2, Harald E. Vonkeman3, G.A. Versteeg1, Arie E. van der Bijl4 and Mart A.F.J. van de Laar1, 1Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 2Psychology, Health & Technology, University of Twente, Enschede, Netherlands, 3Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 4Isala Klinieken, Zwolle, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Early Rheumatoid Arthritis, remission and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Presently the goals of rheumatoid arthritis (RA) therapy are to control symptoms, to prevent joint damage and disability.  Attaining long-term clinical remission or at least low disease activity (LDA) is mandatory to reach these goals. Treat-to-target (T2T) protocols have been shown to be feasible and superior to non-protocolled care in treating early RA patients in daily clinical practice. However, not all patients may equally benefit from these treatment protocols. Not reaching remission or loss of remission results in periods of moderate to high disease activity in which signs and symptoms impair the health status of patients. Moreover, longer periods of moderate to high disease activity probably affect long term outcome. The objective of the present study was to identify the proportion of RA patients not receiving optimal long-term clinical benefit from T2T therapy.

Methods: Data were used from patients with early RA included in the DREAM remission induction cohort between January 2006 till June 2010. Patients were treated according to a step-up strategy aiming at remission, which consisted of methotrexate, followed by the addition of sulfasalazine and subsequently exchange of sulfasalazine with a TNFi in case of persistent disease activity. Patients were evaluated at the outpatient clinic at baseline and every 3 months thereafter. ESR-DAS28 was used to assess if patients were in LDA (DAS28 ≤3.2) or remission (DAS28 <2.6) at every visit. T2T therapy is considered not fully effective in case the patient’s disease activity is moderate to high over a period of ≥ 6 months. 

Results: Five-year follow-up data were available from 229 patients (63.3% female, mean age 57.7 years). Between 1 and 5 years after disease onset and start of T2T treatment, the mean DAS28 scores over time remained stable and below the cutoff for remission (Figure). In this period however, 67 (29.3%) patients experienced at least one episode of ≥ 6 months with low, moderate or high disease activity (DAS28> 2,6). Moreover, 34 (14.8%) patients experienced at least one episode of ≥ 6 months with moderate or high disease activity (DAS28> 3,2).

Conclusion: At the population level, T2T therapy in early RA results in stable low disease activity. However, even in this very well managed population, a relevant proportion of patients is not always in remission.  This suggests an unmet need that deserves additional study to further improve RA management.


Disclosure: L. M. M. Steunebrink, None; P. M. ten Klooster, None; H. E. Vonkeman, None; G. A. Versteeg, None; A. E. van der Bijl, None; M. A. F. J. van de Laar, None.

To cite this abstract in AMA style:

Steunebrink LMM, ten Klooster PM, Vonkeman HE, Versteeg GA, van der Bijl AE, van de Laar MAFJ. Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/treat-to-target-of-remission-is-effective-but-not-all-patients-are-always-in-remission/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treat-to-target-of-remission-is-effective-but-not-all-patients-are-always-in-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology